Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACXPNASDAQ:BFRGNASDAQ:FLGCNASDAQ:PLRZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$0.43-10.2%$0.42$0.30▼$3.33$11.25M-1.381.65 million shs843,288 shsBFRGBullfrog AI$1.51-3.8%$1.74$1.23▼$4.84$14.78M0.61398,309 shs127,711 shsFLGCFlora Growth$0.61-2.9%$0.65$0.42▼$2.11$14.18M2.04273,008 shs95,973 shsPLRZPolyrizon$0.74+4.8%$39.44$0.55▼$1,200.00$3.76MN/A3.26 million shs449,299 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals-10.25%-21.82%+10.82%+5.29%-80.80%BFRGBullfrog AI-3.82%-8.48%-14.20%-11.18%-12.72%FLGCFlora Growth-2.88%-7.41%-11.39%-6.15%-39.60%PLRZPolyrizon+4.82%+1.37%-28.25%-99.38%+73,899,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACXPAcurx Pharmaceuticals2.7556 of 5 stars3.53.00.00.03.81.70.0BFRGBullfrog AI0.9881 of 5 stars0.04.00.00.02.22.50.0FLGCFlora Growth2.9962 of 5 stars3.35.00.00.03.00.80.6PLRZPolyrizonN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals 3.00Buy$8.001,760.47% UpsideBFRGBullfrog AI 0.00N/AN/AN/AFLGCFlora Growth 2.50Moderate Buy$4.00555.74% UpsidePLRZPolyrizon 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PLRZ, FLGC, BFRG, and ACXP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$8.00(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$0.03 per shareN/ABFRGBullfrog AI$60K237.07N/AN/A$0.57 per share2.65FLGCFlora Growth$59.51M0.23N/AN/A$0.31 per share1.97PLRZPolyrizonN/AN/AN/AN/A$315.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$14.10M-$0.70N/AN/AN/AN/A-526.78%-223.78%8/8/2025 (Estimated)BFRGBullfrog AI-$6.99M-$0.81N/A∞N/AN/A-163.23%-139.94%N/AFLGCFlora Growth-$15.91M-$0.98N/AN/AN/A-24.85%-216.49%-45.56%8/11/2025 (Estimated)PLRZPolyrizon-$1.54MN/A0.00∞N/AN/AN/AN/AN/ALatest PLRZ, FLGC, BFRG, and ACXP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025BFRGBullfrog AIN/A-$0.21N/A-$0.21N/AN/A5/13/2025Q1 2025FLGCFlora Growth-$0.01-$0.04-$0.03-$0.04$14.79 million$11.79 million5/12/2025Q1 2025ACXPAcurx Pharmaceuticals-$0.14-$0.11+$0.03-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/ABFRGBullfrog AIN/AN/AN/AN/AN/AFLGCFlora GrowthN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A1.931.93BFRGBullfrog AIN/A4.874.87FLGCFlora Growth0.881.050.67PLRZPolyrizonN/A10.1610.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%BFRGBullfrog AI0.96%FLGCFlora Growth36.01%PLRZPolyrizonN/AInsider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals26.00%BFRGBullfrog AI33.90%FLGCFlora Growth12.56%PLRZPolyrizonN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals323.48 million17.38 millionOptionableBFRGBullfrog AI49.42 million6.22 millionNot OptionableFLGCFlora Growth28022.57 million19.73 millionNot OptionablePLRZPolyrizonN/A5.33 millionN/AN/APLRZ, FLGC, BFRG, and ACXP HeadlinesRecent News About These CompaniesPolyrizon’s nasal drug delivery system shows promising resultsJune 14, 2025 | uk.investing.comPolyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its ...June 12, 2025 | bakersfield.comBPolyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS TherapeuticsJune 12, 2025 | globenewswire.comPolyrizon Ltd. Receives Nasdaq Notification of Potential Delisting Due to Shareholder Dilution ConcernsMay 23, 2025 | quiverquant.comQPolyrizon Announces Receipt of Nasdaq Delisting NoticeMay 23, 2025 | globenewswire.comPolyrizon Ltd. Announces Reverse Share Split Effective May 27, 2025May 22, 2025 | tipranks.comPolyrizon Emerges with Positive Preclinical Data on Nasal Protection PlatformMay 21, 2025 | globenewswire.comPolyrizon Ltd. Announces Increase in Outstanding Shares Following Warrant ExercisesMay 14, 2025 | tipranks.comPolyrizon Ltd.: Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue TreatmentMay 13, 2025 | finanznachrichten.dePolyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue TreatmentMay 13, 2025 | globenewswire.comPolyrizon, Pheton, AirSculpt: Top 3 Healthcare Stocks With Soaring Weekly Retail InterestMay 5, 2025 | msn.comPolyrizon reports safety study results for PL-14 Allergy Blocker formulationApril 26, 2025 | markets.businessinsider.comPolyrizon Ltd.: Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue ModelApril 25, 2025 | finanznachrichten.dePolyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue ModelApril 25, 2025 | globenewswire.comPolyrizon Ltd. Shareholders Approve Key Amendments at Annual MeetingApril 17, 2025 | tipranks.comPolyrizon Faces Nasdaq Compliance ChallengeApril 11, 2025 | tipranks.comPolyrizon Receives Nasdaq Notification Regarding Minimum Bid RequirementsApril 11, 2025 | globenewswire.comPolyrizon entered into agreement with branding, trademark consultancy firmApril 3, 2025 | markets.businessinsider.comPolyrizon Partners with Branding Firm for Strategic Brand DevelopmentApril 2, 2025 | tipranks.comPolyrizon Engages Leading Branding Firm for Strategic Brand DevelopmentApril 2, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePLRZ, FLGC, BFRG, and ACXP Company DescriptionsAcurx Pharmaceuticals NASDAQ:ACXP$0.43 -0.05 (-10.25%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.44 +0.02 (+3.49%) As of 06/27/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Bullfrog AI NASDAQ:BFRG$1.51 -0.06 (-3.82%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.56 +0.05 (+3.64%) As of 06/27/2025 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.Flora Growth NASDAQ:FLGC$0.61 -0.02 (-2.88%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.62 +0.01 (+1.48%) As of 06/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.Polyrizon NASDAQ:PLRZ$0.74 +0.03 (+4.82%) As of 06/27/2025 04:00 PM EasternPolyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
